Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist

European Journal of Clinical Pharmacology

Volumn 63, Issue 2, 2007, Pages 151-158

  Van Giersbergen, Paul L M ^a   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Clazosentan; Entry into man study; ET receptor antagonist; Intravenous administration

Indexed keywords

CLAZOSENTAN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD ANALYSIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; EPISTAXIS; EXTERNAL OTITIS; FATIGUE; FLU LIKE SYNDROME; HUMAN; MALE; NAUSEA; NORMAL HUMAN; NOSE CONGESTION; PAIN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SHIVERING; SYNCOPE; URINALYSIS; VITAL SIGN; VOMITING;

ADULT; BLOOD PRESSURE; CHROMATOGRAPHY, LIQUID; DIOXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDOTHELIN-1; HALF-LIFE; HEADACHE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NASAL OBSTRUCTION; NAUSEA; PYRIDINES; PYRIMIDINES; RECEPTOR, ENDOTHELIN A; SULFONAMIDES; TETRAZOLES; TISSUE DISTRIBUTION; VOMITING;

EID: 33846445687     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0117-z     Document Type: Article

References (21)

1. Pernow J, Ahlborg G, Lundberg JM, Kaijser L (1997) Long-lasting coronary vasoconstrictor effects and myocardial uptake of endothelin-1 in humans. Acta Physiol Scand 159:147-153
2. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411-415
3. Lüscher TF, Barton M (2000) Endothelins and endothelin receptor antagonists. Therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102:2434-2440
4. Spieker LE, Noll G, Luscher TF (2001) Therapeutic potential for endothelin receptor antagonists in cardiovascular disorders. Am J Cardiovasc Drugs 1:293-303
5. Ray A, Hegde LG, Chugh A, Gupta JB (2000) Endothelin-receptor antagonists: current and future perspectives. Drug Discov Today 5:455-464
6. Roux S, Breu V, Giller T, Neidhart W, Ramuz H, Coassolo P, Clozel JP, Clozel M (1997) Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther 283:1110-1118
7. Dorsch NWC, King MT (1994) A review of cerebral vasospasm in aneurysmal subarachnoid haemorrhage. J Clin Sci 1:19-26
8. Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, Breu V, Schmiedek P (2005) Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled multicenter Phase IIa study. J Neurosurg 103:9-17
9. Treinen KA, Louden C, Dennis MJ, Wier PJ (1999) Developmental toxicity and toxicokinetics of two endothelin receptor antagonists in rats and rabbits. Teratology 59:51-59
10. Gibaldi M, Perrier D (1982) Pharmacokinetics. Dekker, New York
11. Gough K, Hutchison M, Keene O Byrom B, Ellis S, Lacey L, McKellar J (1995) Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Inf J 29:1039-1048
12. Buoen C, Bjerrum OJ, Thomsen MS (2005) How first-time-in-human studies are being performed: a survey of phase I dose-escalation trials in healthy volunteers published between 1995 and 2004. J Clin Pharmacol 45:1123-1136
13. Dingemanse J, Clozel M, van Giersbergen PLM (2002) Entry-into-man study with tezosentan, an intravenous dual endothelin receptor antagonist. J Cardiovasc Pharmacol 39:795-802
14. Weber C, Schmitt R, Birnboeck H, Hopfgartner G, van Marle SP, Peeters PAM, Jonkman JHG (1996) Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 60:124-137
15. Freed MI, Wilson DE, Thompson KA, Harris RZ, Ilson BE, Jorkasky DK (1999) Pharmacokinetics and pharmacodynamics of SB 209670, an endothelin receptor antagonist: effects on the regulation of renal vascular tone. Clin Pharmacol Ther 65:473-482
16. Dingemanse J, Clozel M, van Giersbergen PLM (2002) Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects. Br J Clin Pharmacol 53:355-362
17. van Giersbergen PLM, Bodin F, Dingemanse J (2002) Cyclosporine increases the exposure to tezosentan, an intravenous dual endothelin receptor antagonist. Eur J Clin Pharmacol 58:243-245
18. Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, Webb DJ (1998) Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 97:752-756
19. Dingemanse J, Gunawardena KA, van Giersbergen PLM (2006) Comparison of the pharmacokinetics, pharmacodynamics, and tolerability of tezosentan between Caucasian and Japanese subjects. Br J Clin Pharmacol 61:405-413
20. 4. J Nutr 129:722-727
21. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M (1994) Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 199:1461-1465